CN115530308A - Composite active hyaluronic acid beverage and preparation method thereof - Google Patents
Composite active hyaluronic acid beverage and preparation method thereof Download PDFInfo
- Publication number
- CN115530308A CN115530308A CN202211294546.3A CN202211294546A CN115530308A CN 115530308 A CN115530308 A CN 115530308A CN 202211294546 A CN202211294546 A CN 202211294546A CN 115530308 A CN115530308 A CN 115530308A
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- beverage
- food
- compound active
- molecular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 184
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 183
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 179
- 235000013361 beverage Nutrition 0.000 title claims abstract description 81
- 239000002131 composite material Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 14
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 14
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 14
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000004386 Erythritol Substances 0.000 claims abstract description 11
- 235000019414 erythritol Nutrition 0.000 claims abstract description 11
- 229940009714 erythritol Drugs 0.000 claims abstract description 11
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 11
- 239000008213 purified water Substances 0.000 claims abstract description 11
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 21
- 235000005152 nicotinamide Nutrition 0.000 claims description 17
- 239000011570 nicotinamide Substances 0.000 claims description 17
- 229960003966 nicotinamide Drugs 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 3
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 38
- 210000001508 eye Anatomy 0.000 abstract description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- 210000001503 joint Anatomy 0.000 abstract description 4
- 210000000214 mouth Anatomy 0.000 abstract description 4
- 238000013270 controlled release Methods 0.000 abstract description 3
- 230000031891 intestinal absorption Effects 0.000 abstract description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract description 2
- -1 hyaluronic acid compound Chemical class 0.000 abstract 7
- 230000000052 comparative effect Effects 0.000 description 27
- 230000000694 effects Effects 0.000 description 14
- 208000006820 Arthralgia Diseases 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 206010067171 Regurgitation Diseases 0.000 description 8
- 206010040954 Skin wrinkling Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000003777 Interleukin-1 beta Human genes 0.000 description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000003796 beauty Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002087 whitening effect Effects 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 5
- 206010023232 Joint swelling Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007493 shaping process Methods 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001179 synovial fluid Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- 238000012371 Aseptic Filling Methods 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 241000561734 Celosia cristata Species 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007117 Oral Ulcer Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000001520 comb Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 230000037070 skin defense Effects 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000027993 eye symptom Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 125000000627 niacin group Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a compound active hyaluronic acid beverage, relating to the technical field of beverage preparation, wherein the beverage comprises the following components: food-grade high-molecular hyaluronic acid, food-grade small-molecular hyaluronic acid, grape seed extract, nicotinamide, erythritol, edible essence and purified water, wherein hyaluronic acid with different molecular weights is combined to form composite active hyaluronic acid, and the mass fraction of the composite active hyaluronic acid is 0.01-0.05 percent (g/100 ml). The hyaluronic acid gel contains hyaluronic acid molecules with various molecular weights, so that the intestinal absorption rate is promoted, and the bioavailability is improved; the hyaluronic acid compound active hyaluronic acid beverage also covers various needs of organisms, such as skin, joints, eyes, gastrointestinal tracts, oral cavities and the like, the hyaluronic acid can be stably supplemented by the slow-release gradient and the controlled-release gradient of the hyaluronic acid compound active hyaluronic acid beverage, the hyaluronic acid compound active hyaluronic acid beverage can adapt to various crowds, the applicability of the hyaluronic acid compound active hyaluronic acid beverage is improved, the compliance of people can be effectively improved by the hyaluronic acid existing in the form of the hyaluronic acid beverage, the preparation method of the hyaluronic acid compound active hyaluronic acid beverage is simple, the hyaluronic acid compound active hyaluronic acid beverage is easy to produce, and the hyaluronic acid compound active hyaluronic acid beverage can be used for people with different requirements by adjusting hyaluronic acid with different molecular masses.
Description
Technical Field
The invention relates to the technical field of beverage preparation, in particular to a compound active hyaluronic acid beverage and a preparation method thereof.
Background
With the increasing demand of people on beauty, skin care, anti-wrinkle and anti-aging, the common related products in the market are in the forms of local injection, external application by smearing, concentrated oral liquid and the like, and the problems of operation, wound reaction, anaphylactic reaction, swelling, limited and single product reaching position, poor compliance and the like of professionals exist.
Hyaluronic acid, also known as hyaluronic acid (hyaluronan acid), was originally isolated from the vitreous body of bovine eyes and is widely found in nature in various tissue organs of humans and animals, such as the eyes, skin, joint cavities, blood vessels, and brain. Hyaluronic acid is a non-sulfated glycosaminoglycan component, and is a disaccharide unit structure formed by connecting D-glucuronic acid and N-acetylglucosamine through a beta-1,3 glycosidic bond. Hyaluronic acid is present in connective tissues such as skin, synovial fluid and vitreous humor at a high concentration, and has effects of lubricating, buffering stress and nourishing joints. Hyaluronic acid is dynamically present in the human body, and the daily degradation and resynthesis amount is about one third of the total amount of hyaluronic acid, so as to ensure that hyaluronic acid plays the best physiological effect. The hyaluronic acid has high water retention capacity and can play important physiological functions of cell nutrient substance transportation, cell interaction, wound healing, lubrication and the like. Compared with local injection, the oral hyaluronic acid has unique advantages such as no damage, good compliance, systemic distribution and the like. Has important significance for promoting the development of related industries.
About 80% of hyaluronic acid with molecular mass of 900KD can be absorbed by human body after oral administration, and then can be transferred to skin and joint cavity. The absorption effect of orally administered hyaluronic acid is correlated with its relative molecular mass, and the absorption mode, absorption site, distribution range and route of entering blood circulation are different in vivo after oral administration of hyaluronic acid. Hyaluronic acid with molecular mass above 100KD can not be directly absorbed by cells, hyaluronic acid with molecular mass within 70KD can directly permeate into intestinal epithelial cells, and hyaluronic acid with molecular mass less than 5KD can also enter into cells through passive diffusion. After being taken orally, the high-molecular hyaluronic acid needs to enter cells through endocytosis and endocytosis, and after degradation, the fragments are discharged out of the cells through exocytosis to exert the biological effect. After hyaluronic acid enters the intestinal tract, the hyaluronic acid is degraded by the hyaluronidase contained in the intestinal microorganisms to become unsaturated hyaluronic acid, and then the unsaturated hyaluronic acid can be absorbed by colonic epithelial cells and transported to a plurality of parts such as skin, articular cavity and the like through blood circulation.
Hyaluronic acid has been widely recognized and verified as having effects of maintaining moisture, shaping beauty, maintaining elasticity, and increasing skin defense function on the skin. A randomized, double-blind, placebo-controlled clinical study showed that oral hyaluronic acid increased skin moisture, improved skin dryness, and also had antioxidant efficacy. The ingestion of hyaluronic acid also helps to stimulate the synthesis of hyaluronic acid per se and promote the proliferation of skin fibroblasts. Oral hyaluronic acid also increases the moisture content of the skin after UV irradiation and reduces the rate of wrinkle formation and skin aging. Clinical research results carried out by dermatology of the medical center of eastern university of Japan suggest that orally administering 120mg of hyaluronic acid with high molecular mass of 300KD or hyaluronic acid with low molecular mass of 2KD can significantly improve the skin glossiness and flexibility of the subject and lighten the facial crow's feet after lasting for 12 weeks. The research result also shows that the hyaluronic acid with small molecular mass has stronger activities of scavenging oxygen free radicals and resisting oxidation compared with the high molecular mass, so that the hyaluronic acid with small molecular mass can obviously reduce the oxidative stress reaction of ultraviolet irradiation on the skin.
Hyaluronic acid is an important component of synovial fluid in joint cavities, the reduction of the concentration and molecular mass of endogenous hyaluronic acid is an important reason for the reduction of the viscoelasticity of the synovial fluid and the release of inflammatory mediators in joints, and clinical researches with double blindness, placebo control and random design show that the oral hyaluronic acid can improve the symptoms of gonarthromeningitis and relieve joint pain, swelling and inflammatory reaction. After 8 weeks of continuous oral administration of hyaluronic acid, the patient with arthralgia can feel that the pain and stiffness of the patient are obviously relieved. When the hyaluronic acid extracted from cockscomb is orally taken by knee osteoarthritis patients, the symptoms of joint pain can be obviously relieved, cartilage degradation of athletes can be weakened, and bone shaping can be promoted. The mechanism of hyaluronic acid for alleviating joint pain and inflammatory reaction is that it can directly regulate the immune response of the body, inhibit the release of inflammatory factors of joint cavities, and produce downstream active ingredients such as glycosaminoglycan to exert the effect of improving joint pain.
Hyaluronic acid, as a topical drug, has been widely used in the treatment of ocular diseases such as dry eye, to enhance lubrication and promote healing of corneal epithelial wounds. Clinical studies in a control group showed that, when compared with topical application of hyaluronic acid alone, oral administration of 240mg 390KD hyaluronic acid daily could significantly improve the therapeutic effect, and the effect of oral administration in combination with topical application of hyaluronic acid was significantly better than that of the topical application alone. The hyaluronic acid can also promote the healing process of corneal epithelial wounds by oral administration, and hyaluronic acid and degradation products thereof can promote epithelial cell proliferation, regulate apoptosis, neovascularization reaction and the like, thereby treating eye diseases.
Hyaluronic acid also has immunoregulation characteristics, and can activate macrophages, dendritic cells and regulatory T cells, induce the expression of antibacterial peptide, and improve intestinal flora, thereby playing the roles of resisting inflammation and repairing intestinal barriers. The hyaluronic acid is a glycosaminoglycan with high molecular weight, can be self-assembled into a net structure and a molecular framework, covers esophageal mucosa to form a mechanical barrier, repairs mucosal injury, promotes hyperplasia and differentiation of esophageal mucosa epithelial cells, weakens the stomach burning sensation and acid regurgitation of patients with gastroesophageal reflux, completely disappears in the process of orally taking hyaluronic acid by half of patients, and can also play a role in treating recurrent oral mucosal ulcer diseases.
The safety research of the oral hyaluronic acid has been long since, the hyaluronic acid content in cockscombs is high, and the hyaluronic acid has been enjoyed as a delicious food in western countries and China for many years. Hyaluronic acid was approved by the japanese government as a dietary supplement in 1992 for improving skin health, relieving joint pain, and the like. Hyaluronic acid is also used as a food additive and a health functional food in countries such as the united states, canada, italy, korea, belgium, and the like. China also approves to expand the application range of hyaluronic acid from simple health care products to common food in 2021 month. Hyaluronic acid has no immunogenicity, is not an allergen, has no risk of causing tumor and teratogenesis, and has high safety. In many double-blind, randomized, controlled-design clinical studies, 200mg hyaluronic acid per day for 1 year, or 240mg hyaluronic acid per day for 8 weeks, or 60mg hyaluronic acid per day for 4 months, no adverse reactions were observed. Animal experiments also show that the continuous oral administration of the hyaluronic acid reaches 1330mg/kg, and the continuous oral administration of the hyaluronic acid for 3 months does not cause toxic effect on rabbits. All show that the oral hyaluronic acid has high safety.
For many years, grape seed extract has been reputed as skin vitamin and oral cosmetics, has the effects of protecting the collagen content in skin, improving the elasticity and luster of the skin, whitening, moisturizing, removing freckles and the like, and can reduce wrinkles and keep the skin soft and smooth; removing acne and healing scar.
In recent years, the role of niacinamide in the field of beauty has become more and more important, and niacinamide is a derivative of vitamin B3 and is one of the skin anti-aging active ingredients acknowledged in the field of beauty skin science. Nicotinamide can inhibit the transfer of melanocyte melanin, thereby achieving the effect of whitening. The appropriate amount of nicotinamide will help improve the energy status of the cells, help the cells mature, and promote the health of various functions of the cells, thus being beneficial to the establishment of the skin barrier function. Nicotinamide enhances skin barrier function by increasing ceramide content in the stratum corneum, and reduces transdermal water loss. The most important effect of the nicotinamide on the anti-aging aspect of the skin is to relieve and prevent dark and yellow complexion generated in the early aging process of the skin, and simultaneously repair the damaged stratum corneum lipid barrier and improve the skin resistance; also has the deep water locking effect to a certain degree.
However, the absorption process and therapeutic effect of hyaluronic acid of different molecular masses vary greatly. Hyaluronic acid with molecular weight above 500KD has better mucosa protection effect, and hyaluronic acid with molecular weight of 10-500KD has better absorption capacity and skin penetration capacity. Products that provide for the addition of molecular mass hyaluronic acid in proportions are still emerging for people with different needs, such as people who wish to relieve joint pain and inflammatory symptoms, have a need for beauty, wrinkle removal, anti-aging, have a need for improving eye discomfort or have a need for improving eyesight, and consumers who wish to regulate the state of the gastrointestinal tract. At present, most of oral hyaluronic acid in the market is health-care oral liquid, and has the defects of high concentration, poor mouthfeel, insufficient compliance, single molecular mass, poor absorption and the like. There is no multi-molecular mass concentration gradient oral hyaluronic acid available as a beverage, and based on this, the present invention proposes a method to solve the above-mentioned problems.
Disclosure of Invention
The invention provides a compound active hyaluronic acid beverage and a preparation method thereof, and solves the problems that most of oral hyaluronic acid provided in the background art is health-care product oral liquid, and has high concentration, poor taste, insufficient compliance, single molecular mass, poor absorption and the like.
The invention provides the following technical scheme: a compound active hyaluronic acid beverage comprises the following components: the food-grade polymer hyaluronic acid is 0.01-0.05 percent of composite active hyaluronic acid by mass per 100ml;
the beverage comprises the following components in percentage by weight: the food-grade high-molecular hyaluronic acid accounts for 30-45% of the composite active hyaluronic acid, the food-grade low-molecular hyaluronic acid accounts for 55-70% of the composite active hyaluronic acid, the grape seed extract accounts for 0.2-1.2% of the beverage, the nicotinamide accounts for 0.03-0.05% of the beverage, and the balance erythritol, edible essence and purified water.
Preferably, the molecular weight of the food-grade high polymer hyaluronic acid is 500-1200KD, and the food-grade high polymer hyaluronic acid is liquid.
Preferably, the molecular weight of the food-grade micromolecular hyaluronic acid is 10-100KD, and the food-grade micromolecular hyaluronic acid is liquid.
Preferably, the complex active hyaluronic acid comprises hyaluronic acid in different molecular weight regions in any proportion.
The invention provides a preparation method of a compound active hyaluronic acid beverage, which comprises the following steps:
the method comprises the following steps: mixing the food-grade high-molecular hyaluronic acid and the food-grade small-molecular hyaluronic acid according to mass fraction;
step two: adding the grape seed extract into the mixture obtained in the first step according to the mass fraction;
step three: adding the nicotinamide to the mixture obtained in the second step according to the mass fraction;
step four: adding the erythritol and the edible essence into the mixture obtained in the third step according to mass fraction;
step five: adding purified water into the mixture obtained in the fourth step, and adding the mixture to a corresponding volume to enable the final concentration of each effective component to reach a corresponding level;
step six: and sterilizing, filling and sealing the obtained mixture to obtain the finished product of the compound active hyaluronic acid beverage.
Preferably, the mixing temperature of the components in the beverage is 25-40 ℃, and the filling is in an aseptic mode.
Preferably, the sterilization mode can be a high-voltage pulse electric field sterilization mode, the pulse number is 100-300, the field strength is 20-30 kV/cm, and the pulse frequency is 100-300Hz.
Preferably, the sterile filling has a specification of 50-500 mL/bottle, preferably 100 mL/bottle.
The invention also provides application of the compound active hyaluronic acid beverage in improving skin conditions.
In the present invention, the improvement of skin conditions may include moisture retention, shaping beauty, elasticity retention, skin defense function enhancement, wrinkle reduction, whitening, and the like.
The invention also provides application of the compound active hyaluronic acid beverage in improving joint states.
In the present invention, the improvement of the joint condition may include reduction of pain, swelling and discomfort at the joint portion.
The invention also provides application of the compound active hyaluronic acid beverage in improving eye states.
In the present invention, the improvement of the eye state may include improvement of eye dryness, discomfort, and the like.
The invention also provides application of the compound active hyaluronic acid beverage in improving the states of oral cavity and gastrointestinal tract.
In the present invention, the improvement of the oral cavity and gastrointestinal tract state may include the relief of oral ulcer, burning sensation and acid regurgitation in the stomach.
The preferred embodiments of the present invention can be obtained by arbitrarily combining the above-described preferred conditions within an allowable range, based on the knowledge of the ordinary operation in the art.
Compared with the prior art, the invention has the following beneficial effects:
1. the compound active hyaluronic acid beverage and the preparation method thereof contain hyaluronic acid molecules with various molecular weights, can adapt to various crowds, improve the applicability of the beverage, have simple preparation method and easy production, and can aim at the crowds with different requirements by adjusting hyaluronic acid with different molecular weights in the compound active hyaluronic acid beverage.
2. According to the compound active hyaluronic acid beverage and the preparation method thereof, hyaluronic acid in the form of beverage can effectively improve compliance of people, and the compound active hyaluronic acid contained in the beverage can promote intestinal absorption rate and improve bioavailability; and also covers various needs of organisms, such as skin, articular cartilage, eyes and the like, the sustained-release and controlled-release gradient can stably supplement hyaluronic acid, and the absorption and utilization time can be prolonged to 24 hours. The grape seed extract and the nicotinamide with reasonable concentration have multiple effects of improving skin elasticity and luster, whitening, moisturizing and reducing wrinkles, and the characteristics of no sugar, low calorie and healthier skin are also beneficial to popularization and application.
Drawings
FIG. 1 is a schematic view showing the results of detection of microorganisms in beverages according to comparative examples and examples of the present invention;
FIG. 2 is a graph showing the results of the fourth embodiment of the present invention;
FIG. 3 is a diagram illustrating the results of the fifth embodiment of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention provides a compound active hyaluronic acid beverage, which comprises the following components: the hyaluronic acid is characterized by comprising liquid food-grade high-molecular hyaluronic acid with the molecular weight of 500-1200KD, liquid food-grade small-molecular hyaluronic acid with the molecular weight of 10-100KD, grape seed extract, nicotinamide, erythritol, edible essence and purified water, wherein the food-grade high-molecular hyaluronic acid and the food-grade small-molecular hyaluronic acid form composite active hyaluronic acid, the composite active hyaluronic acid comprises the hyaluronic acid in different molecular weight regions in any proportion, and the mass fraction of the composite active hyaluronic acid is 0.01-0.05 percent and g/100ml;
the beverage comprises the following components in percentage by weight: the food-grade high-molecular hyaluronic acid accounts for 30-45% of the composite active hyaluronic acid, the food-grade low-molecular hyaluronic acid accounts for 55-70% of the composite active hyaluronic acid, the grape seed extract accounts for 0.2-1.2% of the beverage, the nicotinamide accounts for 0.03-0.05% of the beverage, and the balance erythritol, edible essence and purified water.
The compound active hyaluronic acid contained in the invention can promote the intestinal absorption rate and improve the bioavailability; and also covers various requirements of organisms such as skin, articular cartilage, eyes and the like, the sustained-release and controlled-release gradient of the hyaluronic acid can stably supplement the hyaluronic acid, and the absorption and utilization time can be prolonged to 24 hours. The grape seed extract and the nicotinamide with reasonable concentration have multiple effects of improving the elasticity and luster of skin, whitening skin, moisturizing and reducing wrinkles. The hyaluronic acid in the form of the beverage can effectively improve the compliance of people, and can be realized by adjusting hyaluronic acid with different molecular masses in the compound active hyaluronic acid beverage aiming at people with different requirements, such as improving gastrointestinal symptoms, eliminating eye symptoms, increasing skin elasticity, removing wrinkles, moisturizing, relieving arthralgia and the like; the characteristics of no sugar, low calorie and healthier property also contribute to popularization and application.
The invention provides a preparation method of a compound active hyaluronic acid beverage, which comprises the following steps:
the method comprises the following steps: adjusting the production mixing temperature of the beverage to 25-40 ℃, and mixing the food-grade high-molecular hyaluronic acid and the food-grade small-molecular hyaluronic acid according to mass fraction;
step two: adding the grape seed extract into the mixture obtained in the first step according to the mass fraction;
step three: adding the nicotinamide into the mixture obtained in the second step according to the mass fraction;
step four: adding erythritol and edible essence into the mixture obtained in the third step according to mass fraction;
step five: adding purified water into the mixture obtained in the fourth step, and adding the mixture to a corresponding volume to enable the final concentration of each effective component to reach a corresponding level;
step six: and sterilizing, aseptic filling and sealing the obtained mixture to obtain the finished product of the compound active hyaluronic acid beverage.
The sterilization mode used in the application can be a high-voltage pulse electric field sterilization mode, the pulse number is 100-300, the field intensity is 20-30 kV/cm, the pulse frequency is 100-300Hz, and the specification of the aseptic filling of the application is 50-500 mL/bottle, preferably 100 mL/bottle.
The beverage provided by the application can be applied to the aspects of improving the states of oral cavity and gastrointestinal tract (relieving oral ulcer, stomach burning sense, acid regurgitation and the like), improving the skin state (keeping moisture, shaping and beautifying, keeping elasticity, increasing the defense function of skin, reducing wrinkles, whitening and the like), improving the joint state (relieving pain, swelling, discomfort and the like of joint parts), improving the eye state (improving dryness and discomfort of eyes and the like) and the like.
The following are several specific examples of the composite active hyaluronic acid beverage and the preparation method thereof.
Detailed description of the preferred embodiment
The compound active hyaluronic acid beverage comprises the following components in parts by weight: the total active hyaluronic acid mass is 0.05g, which comprises 0.0225g of macromolecule hyaluronic acid with molecular weight of 1000KD and 0.0275g of micromolecule hyaluronic acid with molecular weight of 100 KD; 1.2g of grape seed extract; 0.05g of niacinamide. Weighing the effective components with corresponding mass, mixing, adding erythritol and edible essence, and adjusting the mouthfeel. Purified water was added to the above mixture to 100ml.
Example two
The compound active hyaluronic acid beverage comprises the following components in parts by weight: the total active hyaluronic acid mass is 0.01g, which comprises 0.003g of macromolecular hyaluronic acid with molecular weight of 500KD and 0.007g of micromolecular hyaluronic acid with molecular weight of 10 KD; 0.2g of grape seed extract; 0.03g of niacinamide. Weighing the effective components with corresponding mass, mixing, adding erythritol and edible essence, and adjusting the mouthfeel. Purified water was added to the above mixture to 100ml.
EXAMPLE III
The compound active hyaluronic acid beverage comprises the following components in parts by weight: the total active hyaluronic acid mass is 0.03g, wherein the total active hyaluronic acid mass comprises 0.012g of macromolecule hyaluronic acid with molecular weight of 800KD and 0.018g of micromolecule hyaluronic acid with molecular weight of 50 KD; 0.7g of grape seed extract; 0.04g nicotinamide. Weighing the effective components with corresponding mass, mixing, adding erythritol and edible essence, and adjusting the mouthfeel. Purified water was added to the above mixture to make 100ml.
Comparative example 1: the small molecule hyaluronic acid in the beverage was replaced with water, and the other ingredients in the beverage were the same as those in example 1.
Comparative example 2: the small molecule hyaluronic acid in the beverage was replaced with water, and the other ingredients in the beverage were the same as those in example 2.
Comparative example 3 the small molecule hyaluronic acid in the beverage was replaced by water, and the other ingredients in the beverage were the same as those in example 3.
The results of the microbiological indicator test in the beverages of the above comparative examples and the beverages of the examples are shown in fig. 1.
Example four
The beverages in the comparative examples and the beverages in the examples were used to examine the reduction of proinflammatory cytokines by digesting and isolating rheumatoid arthritis synovial cells with 4% type II collagenase, 10% fetal bovine serum at 100% humidity, 5% CO 2 Culturing in the state, collecting cells, inoculating to culture dish at 2X 10 6 Cell/well culture in beverage samples corresponding to example 1, example 2, example 3 and comparative example 1, comparative example 2, comparative example 3Setting a negative control group, respectively extracting 10ml of samples, dripping the samples into a culture dish, repeating each sample for 10 times, continuously culturing for 72 hours, extracting culture supernatant, detecting the contents of inflammatory cytokine interleukin 1 beta (IL-1 beta) and tumor necrosis factor alpha (TNF-alpha) by an enzyme-linked immunosorbent assay (ELISA), and performing comparative analysis between two groups to obtain comparative data on the aspect of relieving the arthritic symptoms, wherein the comparative data are shown in figure 2.
As can be seen from the test results, the cell culture supernatants of example 1, example 2 and example 3 have different degrees of reduction of interleukin 1 beta (IL-1 beta) and tumor necrosis factor alpha (TNF-alpha) contents, and have statistical significance difference (P < 0.05); in comparative example 1, comparative example 2, comparative example 3 and the negative control group, the contents of interleukin 1 beta (IL-1 beta) and tumor necrosis factor alpha (TNF-alpha) in the culture supernatant of RA cells were not statistically significantly different (P > 0.05) from those before intervention.
EXAMPLE five
Effect examples of the beverage:
60 volunteers with dry skin were randomly selected and divided into 6 groups, and the beverages of example 1, example 2, example 3, comparative example 1, comparative example 2 and comparative example 3 were administered 3 times a day with 100ml each time. After 30 days of administration, the skin moisture content of each group of volunteers was tested.
60 skin-unsatisfactory volunteers were randomly selected and divided into 6 groups, and the beverages of example 1, example 2, example 3, comparative example 1, comparative example 2 and comparative example 3 were administered 3 times a day, 100ml each time. After 30 days of administration, each group of volunteers was tested for voluntary skin improvement.
60 volunteers with different degrees of knee joint pain and swelling were randomly selected and divided into 6 groups, and the beverages of example 1, example 2, example 3, comparative example 1, comparative example 2 and comparative example 3 were administered 3 times a day, each 100ml. After 30 days of administration, each group of volunteers was tested for improvement of joint pain.
60 volunteers with acid regurgitation symptoms were randomly selected and divided into 6 groups, and the beverages of example 1, example 2, example 3, comparative example 1, comparative example 2 and comparative example 3 were administered 3 times daily at a dose of 100ml. After 30 days of administration, each group of volunteers was tested for relief from acid regurgitation.
The results of the various sets of tests are shown in FIG. 3.
As can be seen from the test results of each group, after 30 days of intervention with the beverages of example 1, example 2 and example 3, volunteers of each group experience a large proportion of the increase in the moisture content of the skin, the improvement in the skin quality, the reduction in the swelling and pain of joints and the alleviation of the symptom of acid regurgitation, and the proportion accounts for 70-100%. By contrast, after the beverages in the comparative examples 1, 2 and 3 are continuously intervened for 30 days, the proportion of the corresponding increase of the skin moisture content, the improvement of the skin quality, the alleviation of the joint swelling and pain and the alleviation of the acid regurgitation symptoms of all groups of volunteers is lower, and the proportion is 0-40%.
Therefore, the beverage prepared by the invention is beneficial to improving the moisture content of the skin, improving the skin quality, relieving joint swelling and pain and relieving acid regurgitation symptoms.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (7)
1. A compound active hyaluronic acid beverage is characterized in that: the beverage comprises the following components: the food-grade polymer hyaluronic acid is 0.01-0.05 percent of composite active hyaluronic acid by mass per 100ml;
the beverage comprises the following components in percentage by weight: the food-grade high-molecular hyaluronic acid accounts for 30-45% of the composite active hyaluronic acid, the food-grade low-molecular hyaluronic acid accounts for 55-70% of the composite active hyaluronic acid, the grape seed extract accounts for 0.2-1.2% of the beverage, the nicotinamide accounts for 0.03-0.05% of the beverage, and the balance erythritol, edible essence and purified water.
2. The compound active hyaluronic acid beverage of claim 1, wherein: the molecular weight of the food-grade high polymer hyaluronic acid is 500-1200KD, and the food-grade high polymer hyaluronic acid is liquid.
3. The composite active hyaluronic acid beverage according to claim 1, wherein: the molecular weight of the food-grade micromolecule hyaluronic acid is 10-100KD, and the food-grade micromolecule hyaluronic acid is liquid.
4. The compound active hyaluronic acid beverage of claim 1, wherein: the compound active hyaluronic acid comprises hyaluronic acid in different molecular weight regions in any proportion.
5. The method for preparing a compound active hyaluronic acid beverage according to any of claims 1-4, wherein the method comprises the following steps: the method comprises the following steps:
the method comprises the following steps: mixing the food-grade high-molecular hyaluronic acid and the food-grade small-molecular hyaluronic acid according to mass fraction;
step two: adding the grape seed extract into the mixture obtained in the first step according to the mass fraction;
step three: adding the nicotinamide into the mixture obtained in the second step according to the mass fraction;
step four: adding the erythritol and the edible essence into the mixture obtained in the third step according to mass fraction;
step five: adding purified water into the mixture obtained in the fourth step, and adding the mixture to a corresponding volume to enable the final concentration of each effective component to reach a corresponding level;
step six: and sterilizing, filling and sealing the obtained mixture to obtain the finished product of the compound active hyaluronic acid beverage.
6. The method for preparing a compound active hyaluronic acid beverage according to claim 5, wherein the method comprises the following steps: the mixing temperature of each component in the beverage is 25-40 deg.C, and the filling is in aseptic manner.
7. Use of a complex active hyaluronic acid beverage according to claims 1-6 for improving skin, joint, eye, oral and gastrointestinal conditions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211294546.3A CN115530308A (en) | 2022-10-21 | 2022-10-21 | Composite active hyaluronic acid beverage and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211294546.3A CN115530308A (en) | 2022-10-21 | 2022-10-21 | Composite active hyaluronic acid beverage and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115530308A true CN115530308A (en) | 2022-12-30 |
Family
ID=84736124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211294546.3A Withdrawn CN115530308A (en) | 2022-10-21 | 2022-10-21 | Composite active hyaluronic acid beverage and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115530308A (en) |
-
2022
- 2022-10-21 CN CN202211294546.3A patent/CN115530308A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4542300B2 (en) | Hyaluronic acid accumulation promoter | |
| US6660308B1 (en) | Beverage and additive for the ill | |
| EP2630961A1 (en) | Agent for promoting healing of living body | |
| CN108740863A (en) | A kind of composition of blood-enrich and its preparation method and application | |
| US9993496B1 (en) | Method of administering hyaluronan formulation for supporting joint health | |
| CN105749333B (en) | A kind of hyaluronic acid medical dressing and preparation method thereof | |
| CN100431547C (en) | A triptolide composite preparation for treating osteoarthritis by joint intracavity injection | |
| CN109700998A (en) | A kind of compound skin injury regeneration renovation agent and preparation method thereof | |
| US7494674B2 (en) | Nutraceutical with tart cherries and method of treatment therewith | |
| CN112869073A (en) | Chinese medicinal composition comprising fruits and vegetables for improving human body function and removing harmful toxin, and its preparation method | |
| KR20170139780A (en) | The composition of containing musk rat that can provide the healthy blood vessel | |
| CN115530308A (en) | Composite active hyaluronic acid beverage and preparation method thereof | |
| CN116508917A (en) | Sodium hyaluronate bottle gourd beverage | |
| US10583153B1 (en) | Method of administering hyaluronan formulation for maintaining and supporting joint health | |
| CN101297705B (en) | Compound Tibet sheep placenta capsule for removing wrinkle and resisting aging | |
| US20220088061A1 (en) | Cosmetic/dermatological composition | |
| CN107898806A (en) | A kind of composition and its application with strong anti-inflammatory activity | |
| KR20080087941A (en) | A composition containing the low molecular weight hyaluronic acid for improving skin wrinkles and skin peeling | |
| JP2004083416A (en) | Skin care preparation for external use and food and drink product | |
| CN108635618B (en) | Preparation method of medical adhesive with healing promoting and repairing functions | |
| JP6861955B2 (en) | Hyaluronic acid synthesis accelerator | |
| Hormozi | Plant polysaccharides for orthopedic drug delivery | |
| WO2015015815A1 (en) | Fibroblast activator | |
| CN116491615B (en) | Meinaria oil collagen peptide beverage composition and preparation method thereof | |
| CN116650615B (en) | Composition with oral care effect and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20221230 |
|
| WW01 | Invention patent application withdrawn after publication |